Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
1998-7-10
|
pubmed:abstractText |
Immunosuppressive approaches to combined kidney-pancreas tx include quadruple therapy with either antilymphocyte globulin (ATG) or OKT3 for a short period (7-14 days) immediately after transplantation. Maintenance therapy with prednisone, azathioprine and cyclosporin is then used to ensure the long-term survival of the graft. This study reports 23 cases of combined kidney-pancreas tx under ATG induction (n = 7) and OKT3 induction (n = 16). Both groups had maintenance therapy with azathioprine, prednisone and cyclosporin. The follow-up was 12 months. Graft loss was 3 out of 7 vs 1 out of 16 (p < 0.05) for the kidney and 3 out of 7 vs 3 out of 16 for the pancreas in ATG treated vs OKT3 treated patients respectively. There were two deaths in the ATG group and one in the OKT3 group; two patients died with functioning graft, one in each group. The one year actuarial survival was 87% for graft and patient, 83% for kidney and 77% for pancreas. Combined kidney-pancreas tx with ATG or OKT3 have a similar outcome. OKT3 allows a longer period before the onset of rejection. There is a trend in survivals which suggests a better survival in OKT3 treated recipients. Infections and other complications were similar in ATG and OKT3 patients.
|
pubmed:language |
ita
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Anti-Inflammatory Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Antilymphocyte Serum,
http://linkedlifedata.com/resource/pubmed/chemical/Azathioprine,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclosporine,
http://linkedlifedata.com/resource/pubmed/chemical/Immunosuppressive Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Muromonab-CD3,
http://linkedlifedata.com/resource/pubmed/chemical/Prednisone
|
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
0026-4733
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
53
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
121-8
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:9617106-Adult,
pubmed-meshheading:9617106-Anti-Inflammatory Agents,
pubmed-meshheading:9617106-Antilymphocyte Serum,
pubmed-meshheading:9617106-Azathioprine,
pubmed-meshheading:9617106-Cyclosporine,
pubmed-meshheading:9617106-Female,
pubmed-meshheading:9617106-Follow-Up Studies,
pubmed-meshheading:9617106-Graft Rejection,
pubmed-meshheading:9617106-Graft Survival,
pubmed-meshheading:9617106-Humans,
pubmed-meshheading:9617106-Immunosuppressive Agents,
pubmed-meshheading:9617106-Kidney Transplantation,
pubmed-meshheading:9617106-Male,
pubmed-meshheading:9617106-Middle Aged,
pubmed-meshheading:9617106-Muromonab-CD3,
pubmed-meshheading:9617106-Pancreas Transplantation,
pubmed-meshheading:9617106-Prednisone,
pubmed-meshheading:9617106-Time Factors
|
pubmed:year |
1998
|
pubmed:articleTitle |
[Kidney-pancreas transplantation. Clinical results in 23 consecutive patients].
|
pubmed:affiliation |
Department of Surgery, University of Stanford, USA.
|
pubmed:publicationType |
Journal Article,
Comparative Study,
English Abstract
|